These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32320964)

  • 1. Glycyrrhetinic acid modified MOFs for the treatment of liver cancer.
    Li L; Han S; Yang C; Liu L; Zhao S; Wang X; Liu B; Pan H; Liu Y
    Nanotechnology; 2020 Aug; 31(32):325602. PubMed ID: 32320964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.
    Cheng M; Xu H; Wang Y; Chen H; He B; Gao X; Li Y; Han J; Zhang Z
    Drug Des Devel Ther; 2013; 7():1287-99. PubMed ID: 24187487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
    Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
    Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
    Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
    Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
    Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X; Gu X; Wang H; Yang J; Mao S
    Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
    Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
    Cheng M; Gao X; Wang Y; Chen H; He B; Li Y; Han J; Zhang Z
    Int J Nanomedicine; 2013; 8():4265-76. PubMed ID: 24232303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation and Systemic Delivery of 5-Fluorouracil Conjugated with Silkworm Pupa Derived Protein Nanoparticles for Experimental Lymphoma Cancer.
    Reneeta NP; Thiyonila B; Aathmanathan VS; Ramya T; Chandrasekar P; Subramanian N; Prajapati VK; Krishnan M
    Bioconjug Chem; 2018 Sep; 29(9):2994-3009. PubMed ID: 30089206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
    Cheng M; Ma D; Zhi K; Liu B; Zhu W
    Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil-Loaded Gold Nanoparticles for the Treatment of Skin Cancer: Development, in Vitro Characterization, and in Vivo Evaluation in a Mouse Skin Cancer Xenograft Model.
    Safwat MA; Soliman GM; Sayed D; Attia MA
    Mol Pharm; 2018 Jun; 15(6):2194-2205. PubMed ID: 29701979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
    Dangi R; Hurkat P; Jain A; Shilpi S; Jain A; Gulbake A; Jain SK
    J Microencapsul; 2014; 31(5):479-87. PubMed ID: 24697169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.
    Li X; Xu Y; Chen G; Wei P; Ping Q
    Drug Dev Ind Pharm; 2008 Jan; 34(1):107-15. PubMed ID: 18214762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategy for chemotherapeutic delivery using a nanosized porous metal-organic framework with a central composite design.
    Li Y; Li X; Guan Q; Zhang C; Xu T; Dong Y; Bai X; Zhang W
    Int J Nanomedicine; 2017; 12():1465-1474. PubMed ID: 28260892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Cysteine conjugated poly L-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissues in vivo.
    Mishra BJ; Kaul A; Trivedi P
    Drug Deliv; 2015 Feb; 22(2):214-22. PubMed ID: 24524408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic targeting of glycyrrhetinic acid
    Zhou M; Li S; Shi S; He S; Ma Y; Wang W
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):1105-1113. PubMed ID: 32880189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.